Dry Mouth: a Clinical Guide on Causes, Effects and Treatments, DOI 10.1007/978-3-642-55154-3 214 Index
Index A autoimmune hepatitis , 16 Acupuncture, SGD management , 61 chronic infl ammatory bowel diseases , Adult stem cells , 201–203 15–16 Afferent signalling, MISGD , 39–40 chronic infl ammatory connective tissue Aggregatibacter actinomycetemcomitans , diseases , 9–14 87, 89, 96 endocrine diseases , 17–18 Alpha-2 adrenoceptor (α2Ad) agonists neurological diseases , 18–20 activation , 44–45 primary biliary cirrhosis , 16 central signalling , 43–44 primary sclerosing cholangitis , 16 Alzheimer’s disease (AD) , 19–20 sarcoidosis , 14 American College of Rheumatology Autoimmune hepatitis (AIH) , 16 (ACR) , 13 American-European classifi cation criteria, Sjögren’s syndrome , 9, 10 B Amifostine , 198 Battery-type approaches Amphetamine , 44 Challacombe scale , 107 Amyloidosis , 16 item content , 106 Anorexia nervosa , 23 summated rating scale , 108–111 Antimuscarinic effect , 42 visual analogue scale , 107–108 Arc therapies , 161 Bell’s palsy , 19 Artifi cial salivas BMS. See Burning mouth syndrome (BMS) acidic pH , 170 Bother 1 xerostomia index (BI1) , 130, 131 advantage , 181 Bother 5 xerostomia index (BI5) , 129–131 bioactives , 169 Bulimia nervosa , 23 carboxymethylcellulose/xanthan gum , 169 Burning mouth syndrome (BMS) , 20 composition , 169–170 defi ciency , 165 effi cacy , 168 C elasticity , 170, 171 Candida albicans , 86–87, 90, 94, 95 food proteins , 171 Carbonic anhydrase VI , 74 intraoral lubrication and hydration , Cell models of oral mucosa , 168 167–168 Cerebral palsy syndromes , 18 and natural salivas, physical properties , Cevimeline, MIX treatment , 46 170, 171 Challacombe scale , 4, 107 randomised controlled trial , 166 Chewing gum surface tension , 168 and lozenges , 177 usage , 167 and saliva substitutes , 46–47 viscosity , 165 SGD management , 59 Autoimmune diseases side effects , 59 amyloidosis , 16 sugar-free , 96, 123, 181–182 © Springer-Verlag Berlin Heidelberg 2015 213 G.
[Show full text]